Cart
sales@molnova.com
Sorbinil
CAS No. 68367-52-2
Sorbinil( —— )
Catalog No. M24697 CAS No. 68367-52-2
Sorbinil is an Aldose reductase inhibitor. Sorbinil plays a therapeutic role in treating diabetes and diabetic complications decreases AR activity and inhibit the polyol pathway.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 90 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 330 | In Stock |
|
| 50MG | 516 | In Stock |
|
| 100MG | 728 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSorbinil
-
NoteResearch use only, not for human use.
-
Brief DescriptionSorbinil is an Aldose reductase inhibitor. Sorbinil plays a therapeutic role in treating diabetes and diabetic complications decreases AR activity and inhibit the polyol pathway.
-
DescriptionSorbinil is an Aldose reductase inhibitor. Sorbinil plays a therapeutic role in treating diabetes and diabetic complications decreases AR activity and inhibit the polyol pathway.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetReductase
-
RecptorAldose reductase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number68367-52-2
-
Formula Weight236.2
-
Molecular FormulaC11H9FN2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:20mg/mL
-
SMILESO=C(C1(c(cc(cc2)F)c2OCC1)N1)NC1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huang Q, et al. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications. Med Chem. 2019;15(1):3-7.
molnova catalog
related products
-
Imirestat
Imirestat is an aldose reductase inhibitor that can be used in diabetes research.
-
Alrestatin
Alrestatin is a specific inhibitor of aldose reductase and attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in vitro.
-
WJ-39
WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.
